A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers.

Trial Profile

A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Acronyms SPH
  • Sponsors Hanwha Chemical
  • Most Recent Events

    • 03 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top